Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer

Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and economic value of therapeutic agents. Quality-adjusted life years and incremental cost-effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Peter Paul, Eton, Omar, Garrison, Louis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724271/
https://www.ncbi.nlm.nih.gov/pubmed/31481112
http://dx.doi.org/10.1186/s40425-019-0707-9
_version_ 1783448955167703040
author Yu, Peter Paul
Eton, Omar
Garrison, Louis P.
author_facet Yu, Peter Paul
Eton, Omar
Garrison, Louis P.
author_sort Yu, Peter Paul
collection PubMed
description Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and economic value of therapeutic agents. Quality-adjusted life years and incremental cost-effectiveness ratios are clinical and economic metrics that can be used to evaluate the value of immune checkpoint inhibitors. This Commentary provides perspective on the limitations, benefits, and potential enhancement of this approach to support value-based medicine.
format Online
Article
Text
id pubmed-6724271
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67242712019-09-10 Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer Yu, Peter Paul Eton, Omar Garrison, Louis P. J Immunother Cancer Commentary Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and economic value of therapeutic agents. Quality-adjusted life years and incremental cost-effectiveness ratios are clinical and economic metrics that can be used to evaluate the value of immune checkpoint inhibitors. This Commentary provides perspective on the limitations, benefits, and potential enhancement of this approach to support value-based medicine. BioMed Central 2019-09-03 /pmc/articles/PMC6724271/ /pubmed/31481112 http://dx.doi.org/10.1186/s40425-019-0707-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Yu, Peter Paul
Eton, Omar
Garrison, Louis P.
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
title Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
title_full Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
title_fullStr Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
title_full_unstemmed Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
title_short Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
title_sort challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of cancer
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724271/
https://www.ncbi.nlm.nih.gov/pubmed/31481112
http://dx.doi.org/10.1186/s40425-019-0707-9
work_keys_str_mv AT yupeterpaul challengesinassessingtheclinicalutilityandeconomicvalueofimmunecheckpointinhibitortherapiesofcancer
AT etonomar challengesinassessingtheclinicalutilityandeconomicvalueofimmunecheckpointinhibitortherapiesofcancer
AT garrisonlouisp challengesinassessingtheclinicalutilityandeconomicvalueofimmunecheckpointinhibitortherapiesofcancer

Ejemplares similares